The TASTY-training Study
TASTY-training
Taste and Smell Training in Patients With Cancer Who Are Treated With Tyrosine Kinase Inhibitors: a Multicentre Randomized Intervention Trial
1 other identifier
interventional
90
1 country
11
Brief Summary
A multicentre non-blinded randomised intervention trial with a parallel cluster design. The multicentre study will be performed at 12 hospitals in the Netherlands. A parallel cluster design per hospital was selected to prevent contact between participants in the same hospital who are randomised into different study arms. Such contact may result in bias as it may allow for patients in the control arm to be informed about elements of taste and smell training. To examine the effect of at-home taste and smell training versus standard care on taste function and other outcome parameters, measurements will take place at baseline (before the training starts), and after 12 weeks. The intervention will take place at home. The control group will receive usual care. Questionnaires will be filled in online at home, while taste and smell tests and saliva collection will be conducted either at home or in the hospital during regular visits. Patients in both study arms are contacted by their dietitian every 3 weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2025
Typical duration for not_applicable
11 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 10, 2025
CompletedFirst Submitted
Initial submission to the registry
November 20, 2025
CompletedFirst Posted
Study publicly available on registry
December 2, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2028
July 15, 2026
November 1, 2025
2.6 years
November 20, 2025
July 13, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Taste function
Taste function measured with taste strips at baseline and after week 12 weeks of taste and smell training compared with standard care
12 weeks
Secondary Outcomes (8)
Smell function
12 weeks
Food enjoyment in appetite, hunger and sensory perception
12 weeks
Health-related quality of life
12 weeks
Taste and smell alterations
12 weeks
Risk of malnutrition
12 weeks
- +3 more secondary outcomes
Study Arms (2)
Taste and smell training
EXPERIMENTALTo examine the effect of at-home taste and smell training versus standard care on taste function and other outcome parameters, measurements will take place at baseline (before the training starts), and after 12 weeks. The intervention will take place at home.
No intervention
NO INTERVENTIONStandard of care
Interventions
To examine the effect of at-home taste and smell training versus standard care on taste function and other outcome parameters, measurements will take place at baseline (before the training starts), and after 12 weeks. The intervention will take place at home. The control group will receive usual care. Questionnaires will be filled in online at home, while taste and smell tests and saliva collection will be conducted either at home or in the hospital during regular visits. Patients in both study arms are contacted by their dietitian every 3 weeks.
Eligibility Criteria
You may qualify if:
- Age ≥18 and ≤70 years
- Intention of being treated with tyrosine kinase inhibitors for next 12 weeks.
- Experiencing taste alterations after starting treatment with tyrosine kinase inhibitors
- Consuming solid foods and drinks is possible
- ≤50% of recommended daily intake in kcal consisting of oral nutritional supplements
- Oral mucositis grade ≤2 (Common Terminology Criteria for Adverse Events, version 5.0)
- Ability to comply with all protocol-required actions
- Written informed consent
You may not qualify if:
- Pregnancy
- History of taste, smell, or saliva production dysfunction before treatment with tyrosine kinase inhibitors
- Previous or current radiotherapy of head and neck region
- Enteral feeding through tube or parenteral feeding
- Participation in another clinical trial aimed at preventing or treating taste and/or smell alterations
- Chronic (\>1 month) high dose corticosteroids (\>10 mg prednisone/day or equivalent)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (11)
Amsterdam UMC
Amsterdam, Netherlands
Rijnstate Ziekenhuis
Arnhem, Netherlands
Van Weel-Bethesda Ziekenhuis
Dirksland, Netherlands
Ziekenhuisvoorzieningen Gelderse Vallei
Ede, Netherlands
University Medical Center Groningen
Groningen, 9713 GZ, Netherlands
Martini Ziekenhuis
Groningen, Netherlands
Radboud University medical Center
Nijmegen, Netherlands
Ikazia Ziekenhuis
Rotterdam, Netherlands
Ommelander Ziekenhuis Groningen
Scheemda, Netherlands
Maxima Medisch Centrum
Veldhoven, Netherlands
Isala Klinieken
Zwolle, Netherlands
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
J. J.A. de Haan, MD, PhD
University Medical Center Groningen
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 20, 2025
First Posted
December 2, 2025
Study Start
November 10, 2025
Primary Completion (Estimated)
July 1, 2028
Study Completion (Estimated)
July 1, 2028
Last Updated
July 15, 2026
Record last verified: 2025-11